Volume 13, Number 6—June 2007
Coronaviruses in Children, Greece
To the Editor: Two recently detected human coronaviruses (HCoVs), NL63 and HKU1, increased the number of coronaviruses known to infect humans to 5 (1–3). HCoV-229E and HCoV-NL63 belong to antigenic group 1, HCoV-OC43 and HCoV-HKU1 belong to antigenic group 2, and severe acute respiratory syndrome (SARS)–associated coronavirus (SARS-CoV) is most closely related to group 2 coronaviruses. In 2005, an optimized pancoronavirus reverse transcription–PCR assay was used to explore the incidence of HCoV-NL63 infection in children in Belgium who had a diagnosis of respiratory tract infection (4). We report the results of an epidemiologic study that used a universal coronavirus RT-PCR assay to detect coronaviruses among children in Greece with acute respiratory tract infections.
We tested throat swab specimens obtained from children hospitalized in Greece during June 2003 through May 2004 (200 children 2 months to 14 years of age, mean 4.09 years) and during December 2005 through March 2006 (44 children 1.6–8.5 years of age, mean 5.05). Specimens were obtained the first day of each child’s hospitalization, and all specimens were included in the study, regardless whether other respiratory microorganisms were detected.
The 25-μL reaction contained 200 µM dNTPs, 0.2 µM primer PC2S2 (equimolar mixture of 5′-ttatgggttgggattatc-3′ and 5′-tgatgggatgggactatc-3′), 0.8 µM primer PC2As1 (5′-tcatcagaaagaatcatca-3′), 1 μL of enzyme mix from the QIAGEN One-Step RT-PCR Kit (QIAGEN GmbH, Hilden, Germany), and 5 μL of RNA. The initial 30-min reverse transcription step at 48°C was followed by 10 cycles of 20 sec at 94°C, 30 sec at 62°C with a decrease of 1°C per cycle, 40 sec at 72°C; 40 cycles of 20 sec at 94°C, 30 sec at 52°C, 40 sec at 72°C; and a final extension step at 72°C for 10 min. To determine the sensitivity after optimization, we tested quantified RNA in vitro transcripts that included the natural primer binding sites of the respective coronavirus genomes. Sensitivities for SARS-CoV, HCoV-OC43, HCoV-229E, and HCoV-NL63 were 61.0, 800.0, 8.2, and 82.3 nominal RNA copies per assay, respectively. A separate test was not done for HCoV-HKU1 because it had the same primer binding sites as HCoV-OC43. A phylogenetic tree based on a 400-bp genome fragment of the polymerase gene was constructed (Appendix Figure).
Of 200 samples collected in 2003–2004, 5 (2.5%) were positive for coronaviruses (2 each for HCoV-NL63 and HCoV-229E and 1 for HCoV-OC43), and of 44 samples collected in 2005–2006, 2 (4.5%) were positive for coronaviruses (1 for HCoV-229E and 1 for HCoV-OC43) (GenBank accession nos. EF103180–EF103184, EF394298, and EF394299). CoV-HKU1 was not detected.
The amplified genome region is one of the most conserved regions of the coronavirus genome. However, sequences for HCoV-NL63 strains isolated in Greece are genetically closer to the sequence for a strain (AY567487) isolated in Amsterdam in 2003 (1) than to a strain (AY518894) from a specimen collected in Rotterdam in 1988 (2) (0.6% vs. 1.1% nucleotide divergence). Sequences for HCoV-229E and HCoV-OC43 strains isolated in Greece differ from sequences for strains isolated elsewhere by 0.5%–1.7%.
The HCoV-NL63–positive specimens in our study were obtained from a 9- and a 14-month-old child during winter 2003–2004; no cases were identified during 2005–2006. Specimens positive for HCoV-229E and HCoV-OC43 were detected during both study periods (Table). HCoV-OC43 affected children with a mean age of 3.1 years (median, 1.4 years), and HCoV-229E affected children with a mean (and median) age of 5.5 years. However, no general conclusions can be drawn from these data because number of cases is too few.
None of the patients in Greece had an underlying disease, and all recovered completely. Patients infected with HCoV-229E had been hospitalized for upper respiratory tract infections, and those with HCoV-OC43 had lower respiratory tract infections; all cases were mild. Both children infected with HCoV-NL63 had symptoms of lower respiratory tract infections: 1 child had severe pneumonia and was hospitalized for 12 days, while the other had a mild course of bronchiolitis.
HCoV-NL63 was first identified in Amsterdam, the Netherlands, by van der Hoek et al. (1) from a nasopharyngeal specimen obtained in 2003 from a 7-month-old child with bronchiolitis, conjunctivitis, and fever. One month later, Fouchier et al. (2) reported the characterization of the same virus isolated from a specimen collected in 1988. The specimen had been obtained from an 8-month-old child with pneumonia in Rotterdam, the Netherlands. Later, HCoV-NL63 was detected in 2.5% of bronchiolitis patients <2 years of age in Japan (5) and in most children hospitalized with bronchiolitis in Australia and Canada (6,7).
Coinfection with HCoVs and other respiratory viruses is frequently observed and is associated with severe clinical syndromes, especially in infants and young children (6,8). Coinfection was observed in 3 of the 7 HCoV-positive patients in our study. The 3 patients were infected with HCoV-OC43 or HCoV-229E; coinfection with respiratory syncytial virus was found in 2 patients, and coinfection with Mycoplasma pneumoniae was found in 1 patient. It was not possible to determine the role of the HCoVs in these coinfections. In addition, because coronaviruses can be detected even 3 weeks after an acute episode, some cases of coinfection might represent former rather than current HCoV infection (9).
In conclusion, we detected 3 types of HCoVs in Greece: 229E, OC43, and NL63. This finding provides initial insight into the epidemiologic features of coronaviruses in Greece. Further studies are needed to find the exact clinical effect of these HCoVs in humans and to elucidate the epidemiology of coronaviruses worldwide.
This work was supported by the Greek State Scholarships Foundation (IKY) and the Deutscher Akademischer Austauschdienst (DAAD) (program IKYDA 2004).
- van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, Wolthers KC, Identification of a human coronavirus.Nat Med. 2004;10:368–71.
- Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH, A previously undescribed coronavirus associated with respiratory disease in humans.Proc Natl Acad Sci U S A. 2004;101:6212–6.
- Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, Huang Y, Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia.J Virol. 2005;79:884–95.
- Moës E, Vijgen L, Keyaerts E, Zlateva K, Li S. A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium.BMC Infect Dis. 2005;5:6.
- Ebihara T, Endo R, Ma X, Ishiguro N, Kikuta H. Detection of human coronavirus NL63 in young children with bronchiolitis.J Med Virol. 2005;75:463–5.
- Arden KE, Nissen MD, Sloots TP, Mackay IM. New human coronavirus, HCoV-NL63, associated with severe lower respiratory tract disease in Australia.J Med Virol. 2005;75:455–62.
- Bastien N, Robinson JL, Tse A, Lee BE, Hart L, Li Y. Human coronavirus NL-63 infections in children: a 1-year study.J Clin Microbiol. 2005;43:4567–73.
- Gerna G, Campanini G, Rovida F, Percivalle E, Sarasini A, Marchi A, Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients.J Med Virol. 2006;78:938–49.
- Kaiser L, Regamey L, Roiha H, Deffernez C, Frey U. Human coronavirus NL63 associated with lower respiratory tract symptoms in early life.Pediatr Infect Dis J. 2005;24:1015–7.
Suggested citation for this article: Papa A, Papadimitriou E, Luna LK, Al Masri M, Souliou E, Eboriadou M, et al. Coronaviruses in children, Greece [letter]. Emerg Infect Dis [serial on the Internet]. 2007 Jun [date cited]. Available from http://wwwnc.cdc.gov/eid/article/13/6/06-1353
Comments to the Authors
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: July 01, 2010
- Page last updated: July 01, 2010
- Page last reviewed: July 01, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)